It is understood that the artificial heart has become one of the standardized treatments for heart failure recommended by international guidelines. It is a mechanical pump to deliver blood to the body's circulatory system to assist or replace the pumping function of the natural heart. The majority of heart failure patients show failure of the left ventricle, and many patients only need left ventricular assisted therapy to be able to effectively get through the waiting period for heart transplantation or carry an artificial heart for long term survival, and some patients can have their own heart function fully restored after a period of time with the assistance of an artificial heart so that the artificial heart can be removed.
The international research and development of artificial heart technology began in the 1950s, and has undergone changes from the beating blood pumps listed in the 1990s to the rotary blood pumps listed since the turn of the century. The rotary blood pump is marked by the way the rotor is supported, and has gone through the development process from mechanical contact bearings, liquid dynamic pressure bearings, to full magnetic levitation bearings.
The fully magnetically levitated blood pump is a series of magnets and energized coils arranged in the rotor and pump housing, which make the rotor stable and levitated by the magnetic force between them. This bearing method not only uses blood as a lubricant, but also allows for a much larger levitation gap than liquid dynamic bearings, greatly reducing the level of shear stress to which the blood is subjected. However, full magnetic levitation blood pump involves complex multi-technology, design optimization is very difficult, especially in miniaturization and other aspects face great challenges. It is reported that Concentricity Medical has long insisted on the attack of ultra-compact full magnetic levitation artificial heart, with the help of its own basic patented technology to enter the clinical application, and it has the complete independent intellectual property rights of its product CH-VAD.
It is understood that in 2016, "CH-VAD" products into the national innovative medical device special approval "green channel", the U.S. FDA registration is also synchronized to promote. "CH-VAD" obtained the clinical trial license from the State Drug Administration at the end of 2018, and in March 2019, the first subject was enrolled in the group. Four clinical cases have been completed in Beijing Fuwai Hospital and Huazhong Fuwai Hospital, and all four patients have been discharged in good condition.
It is reported that Lansfan Medical has established the development strategy of deep plowing in the field of cardiovascular and cerebrovascular since the merger of Parsons Brinckerhoff International last year. Lansfan Medical has been focusing on the layout of high-value consumables and low-value consumables. The investment in concentric medical, will further expand its cardiac field of cutting-edge technology development track, enrich the product line, early layout of heart failure, a market full of huge potential.